A new generation of biotech start-ups is trying to “rejuvenate” the liver using mRNA and epigenetic reprogramming. If they succeed, the first true anti-ageing medicines may look less like supplements—and more like cancer drugs for the middle-aged.
When most people imagine an “anti-ageing pill”, they picture a capsule on the bathroom shelf, not an intravenous mRNA infusion designed to make the liver behave as if it were years younger.
Yet that is roughly the bet being placed by NewLimit, a US biotech co-founded by Coinbase chief executive Brian Armstrong. Backed by a war chest of several hundred million dollars,
